Delving into the Latest Updates on RevM10 transduced hematopoietic stem cells(Systemix) with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms-

Target-

Mechanism

Gene transference

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Non-Hodgkin Lymphoma

Originator Organization

Systemix, Inc.

Active Organization-

Inactive Organization

Systemix, Inc.

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
PURPOSE: Phase I/II trial to study the effectiveness of RevM10-treated stem cells plus chemotherapy and peripheral stem cell transplantation in treating patients who have HIV-related non-Hodgkin's lymphoma.

Start Date01 Nov 1998

Sponsor / Collaborator

Systemix, Inc.

[+1]

100 Clinical Results associated with RevM10 transduced hematopoietic stem cells(Systemix)

Login to view more data

100 Translational Medicine associated with RevM10 transduced hematopoietic stem cells(Systemix)

Login to view more data

100 Patents (Medical) associated with RevM10 transduced hematopoietic stem cells(Systemix)

Login to view more data

100 Deals associated with RevM10 transduced hematopoietic stem cells(Systemix)

Login to view more data